S
Science 37
Uses advanced telemedicine technology and patient-centric innovative networked clinical research models to rapidly accelerate biomedical discovery and bring down the costs of clinical trials
Latest news
Press, funding announcements and product moves mentioning Science 37.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Lux Capital- DCdRx Capital
Series B and later11 investors entered at this stage
- AMAmgen
- LBLA BioMed
- AVAmgen Ventures
Glynn Capital Management
Mubadala Capital- PPPPD
- SVSanofi Ventures
- LPLifeSci Venture Partners
- SBSanofi-Genzyme BioVentures
- RGRedmile Group
- NONovartis
Source: Dealroom Talent Intelligence.
Alumni founders
Former Science 37 employees who went on to found companies, sorted by Dealroom signal score.
Belinda TanUnited States
PAPeer AIEst. 2023
Anita ModiUnited States
Kelly ChuUnited States
ABAltis BiosystemsEst. 2015
Michael BironUnited StatesGlobal footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Science 37 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Science 37 on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.